Aquestive Therapeutics (AQST) Income from Continuing Operations (2017 - 2026)

Aquestive Therapeutics' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 8057000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations rose 64.86% year-over-year to 8057000.0; the TTM figure through Mar 2026 stood at 68911000.0 (down 27.05% YoY), while the FY2025 annual figure was 83784000.0, down 89.83% from the prior year.
• Income from Continuing Operations was 8057000.0 for Q1 2026 at Aquestive Therapeutics, up from 31860000.0 in the prior quarter.
• In the past five years, Income from Continuing Operations ranged from a high of 8068000.0 in Q1 2023 to a low of 31860000.0 in Q4 2025.
• Historically, Income from Continuing Operations has averaged 11662235.29 across 5 years, with a median of 12536000.0 in 2022.
• The sharpest annual moves came in 2023 and 2024: Income from Continuing Operations surged 161.03% in 2023, then plunged 465.55% in 2024.
• A 5-year view of Income from Continuing Operations shows it stood at 12352000.0 in 2022, then jumped by 34.33% to 8111000.0 in 2023, then plunged by 110.27% to 17055000.0 in 2024, then tumbled by 86.81% to 31860000.0 in 2025, then surged by 74.71% to 8057000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 8057000.0 (Q1 2026), 31860000.0 (Q4 2025), and 15446000.0 (Q3 2025), per Business Quant data.